Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Abigail Tianai Zhang"'
Autor:
Francesca Barone, Hiroshi Nakashima, James Grant, David Reardon, Kai Wucherpfennig, Patrick Wen, Sean Lawler, Estuardo Aguilar-Cordova, Laura Aguilar, Brian Guzik, E Antonio Chiocca, Scott Rodig, Jessica Dwyer, Isaac Soloman, Daniel Triggs, Abigail Tianai Zhang, Yu Zeng, Jared Woods, Eudocia Quant Lee, Keith Ligon, William Pisano, Mario Suva, Sascha Marx, Simon Gritsch, Nathan Mathewson, David Krisky, Paul Tak
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/3d30837249f94c8eaaf1fa895558ac69
Autor:
Ishaan Ashwini, Tewarie, Alexander W, Senko, Charissa A C, Jessurun, Abigail Tianai, Zhang, Alexander F C, Hulsbergen, Luis, Rendon, Jack, McNulty, Marike L D, Broekman, Luke C, Peng, Timothy R, Smith, John G, Phillips
Publikováno v:
Journal of Neurosurgery. :1-9
OBJECTIVE The incidence of leptomeningeal disease (LMD) has increased as treatments for brain metastases (BMs) have improved and patients with metastatic disease are living longer. Sample sizes of individual studies investigating LMD after surgery fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd7cd7cbea42634d6c851d21be0fbb20
https://doi.org/10.3171/2022.8.jns22744
https://doi.org/10.3171/2022.8.jns22744
Autor:
Jared Woods, Hiroshi Nakashima, David A. Reardon, Sean E. Lawler, Sascha Marx, Anita Giobbie-Hurder, Yu Zeng, Patrick Y. Wen, E. Antonio Chiocca, Jessica Dwyer, Daniel Triggs, Mario L. Suvà, Isaac Soloman, Scott J. Rodig, Kai W. Wucherpfennig, Francesca Barone, Simon Gritsch, William Pisano, Eudocia Q. Lee, Nathan Mathewson, Paul Peter Tak, Abigail Tianai Zhang, Estuardo Aguilar-Cordova, Brian W. Guzik, James Grant, Mariano Severgnini, Keith L. Ligon, Laura K. Aguilar, David Krisky
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundRecurrent high-grade glioma (HGG) represents a significant clinical unmet need with expected survival between 6 to 9 months. Oncolytic viruses are a new therapeutic approach for solid tumors that deploy oncolytic activity combined with loca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1b190074abd8f109e78cb83fbfd6cad
https://doi.org/10.1136/jitc-2021-sitc2021.395
https://doi.org/10.1136/jitc-2021-sitc2021.395
Autor:
Isaac H. Solomon, Estuardo Aguilar-Cordova, E. Antonio Chiocca, Abigail Tianai Zhang, Simon Gritsch, Nathan Mathewson, Hiroshi Nakashima, Patrick Y. Wen, Sean E. Lawler, William Pisano, Eudocia Q. Lee, Mario L. Suvà, James Grant, Daniel Triggs, Scott J. Rodig, Keith L. Ligon, David A. Reardon, Kai W. Wucherpfennig, David Krisky, Laura K. Aguilar
Publikováno v:
Journal of Clinical Oncology. 39:2009-2009
2009 Background: Recurrent glioma patients have few therapeutic options and an expected survival of only 7 to 10 months. New treatments to improve the prognosis of this patient population are a dire medical need. Oncolytic viruses (OVs) are emerging
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f6c70cd0fd9a45bc10264b98f2ada6ab
https://doi.org/10.1200/jco.2021.39.15_suppl.2009
https://doi.org/10.1200/jco.2021.39.15_suppl.2009